BioCryst Pharmaceuticals Inc (NAS:BCRX)
$ 8.11 -0.04 (-0.49%) Market Cap: 1.68 Bil Enterprise Value: 2.24 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 74/100

Q2 2023 BioCryst Pharmaceuticals Inc Earnings Call Transcript

Aug 03, 2023 / 12:30PM GMT
Release Date Price: $7.08 (+1.87%)
Operator

Good day, and welcome to the BioCryst Second Quarter 2023 Earnings Call.

(Operator Instructions)

Please note, this event is being recorded.

I would now like to turn the conference over to Mr. John Bluth with BioCryst. Please go ahead.

John D. Bluth
BioCryst Pharmaceuticals, Inc. - Chief Communications Officer

Thank you very much. Good morning, and welcome to BioCryst's Second Quarter 2023 Corporate Update and Financial Results Conference Call. Today's press release and accompanying slides are available on our website.

Participating with me today are CEO, Jon Stonehouse; CFO, Anthony Doyle; Chief Commercial Officer, Charlie Gayer; and Chief R&D Officer, Dr. Helen Thackray. Following our remarks, we'll answer your questions.

Before we begin, please note that today's conference call will contain forward-looking statements, including those regarding future results, unaudited and forward-looking financial information as well as the company's future performance and/or achievements. These statements are subject to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot